Recursion Pharmaceuticals (RXRX) Current Leases (2022 - 2026)

Recursion Pharmaceuticals (RXRX) has 5 years of Current Leases data on file, last reported at $13.1 million in Q1 2026.

• Quarterly Current Leases rose 10.41% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (up 10.41% YoY) and the FY2025 annual result came in at $12.7 million, down 8.21% from the prior year.
• Current Leases grew to $13.1 million in Q1 2026, from $12.7 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $13.8 million in Q4 2024 to a low of $4.1 million in Q1 2022.
• A 5-year average of $8.2 million and a median of $6.1 million in 2023 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases surged 125.56% — and 2025, when it slipped 8.21%.
• Tracing RXRX's Current Leases over 5 years: stood at $6.0 million in 2022, then climbed by 2.76% to $6.1 million in 2023, then surged by 125.56% to $13.8 million in 2024, then retreated by 8.21% to $12.7 million in 2025, then climbed by 3.35% to $13.1 million in 2026.
• The last three Current Leases figures came in at $13.1 million (Q1 2026), $12.7 million (Q4 2025), and $11.5 million (Q3 2025), per Business Quant data.